20220286
#33775544.0

IRB Approved at the
Protocol Level
Mar 22, 2022

To learn more or to see if you or a loved one may qualify for the study, please contact:

Ricardo Avendano or **Mariana Ramirez**

(949) 899-4161 **(832) 544-3873**

ravendano@lfros.com **lmarianarh@lfros.com**

www.lfrosresearch.com

Do you or a loved one have Uveitis?

If you have non-infectious intermediate-, posterior- or pan-uveitis, you may want to consider participating in the **21103 study.**

21103
CLINICAL STUDY

ACELYRIN

What are clinical studies?

Clinical studies assess new ways to prevent, detect or treat many conditions, including uveitis. They provide valuable information about the safety and effectiveness of potential new medications. Without them no new treatments could be developed.

Clinical studies follow standards and are closely regulated. Every study is reviewed and monitored closely to make sure that the rights of participants are protected, no unnecessary risks are involved and that the study answers important medical questions.

Phase 2 clinical studies include up to a few hundred participants with the condition (e.g. uveitis) for which the study drug is being developed.

The aim of phase 2 studies is to find out:

The effectiveness of the study drug

How much of the study drug is most effective

Learn more about the side effects of the study drug

About the 21103 study

The 21103 study has been designed to assess the effectiveness and safety of izokibep, an investigational* drug for people with uveitis. Izokibep is a new drug that blocks a protein called interleukin (IL-17A), which may reduce inflammation in the eye which is linked to uveitis, although it is not known if the study drug will help you.

**"Investigational" means the study drug is approved for use in clinical research but not yet approved for the treatment of uveitis.*

You may be eligible to take part in this study if you:

Are over 18 years of age

Have a confirmed diagnosis of non-infectious intermediate-, posterior- or pan-uveitis with active disease in at least 1 eye despite treatment with stable doses of corticosteroids

Are currently receiving treatment with oral corticosteroids at a stable dose for at least 2 weeks prior to day 1 of the study

Treatment groups

The 21103 study has four different treatment groups; you will be randomly assigned into 1 of 4 groups:

Group 1	participants will receive placebo once a week, starting from day 1/week 0 to week 51. Group 1 will include about 20 participants.
Group 2	participants will receive placebo once every 2 weeks, starting from day 1/week 0 to week 51. Group 2 will include about 20 participants.
Group 3	participants will receive izokibep 160 mg once a week, starting from day 1/week 0 to week 51. Group 3 will include about 40 participants.
Group 4	participants will receive izokibep 160 mg once every 2 weeks, starting from day 1/week 0 to week 51. Group 4 will include about 40 participants.

All participants in the study will receive a standardized prednisone/prednisolone dose of 60 mg/day at day 1 up to day 14. The dose will then be gradually reduced and stopped by Week 15. If you currently take steroid eye drops, the dose will be reduced gradually and stopped by Week 10.

A placebo is a substance that looks like the investigational drug, but contains no active ingredients. Including placebo in a study helps researchers assess the safety and effectiveness of new investigational drugs. Neither you nor the study doctor will know whether you are receiving placebo or izokibep. Researchers will compare the outcomes between the treatment schedules (dosing once a week or every two weeks) to determine which is most appropriate for people with uveitis.



What will happen if I participate?

Screening for the study can take up to 4 weeks, during this time study doctors will ask you a number of medical questions and you will have health tests to determine if you qualify for this study. The screening period occurs before you get assigned to your treatment group.

If you are eligible to take part, you will return to the study site for 18-20 visits over the course of 65 weeks (51 weeks Treatment period + 14 weeks follow up period) to receive the study drug and monitor your progress as well as your health. During the treatment period you will take the study drug (izokibep) or placebo once every week or once every two weeks. The study drug is administered as a subcutaneous (just below the skin) injection into your upper arm, upper thigh or abdomen.

Study visits

At the study visits, you will have a number of health checks including, vital signs (temperature, pulse, breathing rate, and blood pressure), blood/urine tests, questionnaires about your health and assessments of your eyes and vision. You will talk with the study doctor or team and answer some questions. You will also receive the study drug, based on the schedule that your study doctor will provide. You will be trained how to give yourself the study drug, so that you don't have to attend the clinic as often. The total study duration will be up to 69 weeks (approximately 16.5 months).

- Screening period of up to 28 days (4 weeks)
- Study Intervention period of up to 51 weeks
- Follow-up period of 14 weeks

What next?

If you are interested in the study, you will be given an informed consent form to read and sign. This will provide you with all the study details, including potential risks and benefits, and you will be given a chance to ask any questions you might have before signing the form. You will then complete the screening period to confirm if you are eligible to enter the study.

You would be a volunteer in this study and if during the study you change your mind, you are free to leave at any point. During the study the study drug will be provided to you free of charge.

Thank you for your interest in the 21103 study!

To learn more or to see if you or a loved one may qualify for the study, please contact:

Ricardo Avendano
(949) 899-4161
ravendano@lfros.com

or

Mariana Ramirez
(832) 544-3873
lmarianarh@lfros.com

www.lfrosresearch.com

ACELYRIN